Prime Medicine (PRME) Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine, Inc. (NASDAQ:PRME) is one of the 10 Best Penny Stocks to Buy and Hold Under $5.

On April 15, 2026, Prime Medicine, Inc. (NASDAQ:PRME) announced the appointment of Svetlana Makhni as Chief Financial Officer. In this role, she will lead the company’s financial strategy and operations, including investor relations, financial planning and analysis, and corporate development.

Last month, Oppenheimer initiated coverage of Prime Medicine with an Outperform rating and an $11 price target, describing the company as a key player in the gene editing space. The firm highlighted Prime’s use of prime editing technology, which it views as a leading approach supported by early clinical data and a partnership with Bristol Myers Squibb. Oppenheimer also pointed to the company’s pipeline, including its alpha-1 antitrypsin deficiency (AATD) program, where even modest market penetration could translate into multi-billion-dollar revenue potential. The firm sees significant upside tied to upcoming catalysts over the next 10 to 15 months and noted that elevated short interest appears disconnected from fundamentals.

Prime Medicine (PRME) Appoints Svetlana Makhni as Chief Financial Officer

Pixabay/Public Domain

Earlier in March, Prime Medicine reported FY25 EPS of ($1.35) compared to ($1.65) the prior year, with revenue of $4.63M versus $2.98M. Management emphasized the company’s focus on advancing its prime editing platform to enable durable genetic corrections across a broad set of diseases, with initial efforts centered on PM359, an ex vivo autologous hematopoietic stem cell therapy for chronic granulomatous disease.

Prime Medicine, Inc. (NASDAQ:PRME) develops gene editing-based therapies targeting a range of genetic diseases.

While we acknowledge the risk and potential of PRME as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRME and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.